Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 182, С. 117781 - 117781
Опубликована: Дек. 25, 2024
Язык: Английский
Biological Psychiatry, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
JAMA Psychiatry, Год журнала: 2025, Номер unknown
Опубликована: Апрель 2, 2025
Treatment-resistant depression (TRD) remains a critical challenge in psychiatry, with limited effective options. Esketamine, rapid-acting antidepressant, is usually combined selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine (SNRI), but comparative evidence of these combinations' effectiveness real-world settings sparse. To determine whether the combination esketamine + SNRI shows differences clinical outcomes compared to SSRI patients TRD. This retrospective cohort study was conducted September 2024 using data from TriNetX global health research network, 5-year time window first trial. are drawn and use electronic medical records more than 90 care centers across 20 countries. Adults TRD who were treated either an eligible for inclusion. Treatment (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, vilazodone) (desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine). The primary all-cause mortality, hospitalization, relapse, suicide attempts. Kaplan-Meier survival analysis used estimate probabilities, while risk ratios odds calculated all outcomes. In population-based sample 61 882 adult participants SNRI, 55 480 selected after applying propensity score matching age sex. These divided into 2 matched cohorts: 27 740 (16 007 female [57.7%]; mean [SD] age, 46.0 [21.3] years) 242 [58.6%]; 45.9 [21.9] years). entire population, incidence hospitalizations, depressive relapses, attempts low throughout period. Patients group had significantly lower mortality (5.3% vs 9.1%; P < .001), hospitalization rates (0.1% 0.2%; relapses (14.8% 21.2%; .001) group, which instead showed suicidal (0.3% 0.5%; = .04). this study, among sample, low. slightly
Язык: Английский
Процитировано
0
Опубликована: Ноя. 11, 2024
Abstract While ketamine is already approved for treatment resistant depression in adult patients, its efficacy and safety profile use adolescence still needs further investigations. Preclinical studies proved dose- sex-dependent effects induced by during adolescence, but few have evaluated the short- long-term of at doses necessary to induce antidepressant-like effects. The present study aimed evaluating (1, 5 or 10 mg/kg; vs. vehicle; 1 7 days) naïve early-life stressed (i.e., maternal deprivation) rats both sexes forced-swim novelty-suppressed feeding tests. Safety was measuring psychomotor- reinforcing-like responses adolescent ketamine. In addition, adulthood level cognitive performance, addiction liability (induced a challenge dose treated with ketamine). main results reinforced potential as an antidepressant different ranges each sex. However, some concerns emerged female signs sensitization used antidepressant) male when re-exposed adulthood), suggesting need caution research before moving forward adolescence.
Язык: Английский
Процитировано
0
Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry, Год журнала: 2024, Номер 17(3), С. 493 - 506
Опубликована: Дек. 22, 2024
Major depressive disorder is a public health issue that negatively impacts quality of life and leads to cognitive impairments, causing significant disruptions in work, education, social life. Treatment-resistant depression defined as the failure achieve improvement symptoms despite use at least two different antidepressant medications adequate doses durations. Current pharmacological approaches are inadequate for about half treatment-resistant patients, effects these on impairments limited. Therefore, there need new effective treatment methods. This review aims evaluate ketamine esketamine functions patients. Relevant literature has been reviewed recent studies have evaluated. The results randomized controlled trials indicate treating can improve specific domains. Significant improvements such visual memory, processing speed, working attention recorded patients responding 0.5 mg/kg infusion. However, long-term may negative spatial memory. Esketamine, an NMDA receptor antagonist, shown rapid outcomes, providing stability or functions. Additionally, its intranasal administration offers practical advantages. findings suggest high neurotoxic impact both drugs vary depending dose, duration use, frequency administration. In conclusion, while show potential symptoms, further research needed regarding their safety.
Язык: Английский
Процитировано
0
Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 182, С. 117781 - 117781
Опубликована: Дек. 25, 2024
Язык: Английский
Процитировано
0